Medical devices, healthcare technology and the business of care
PMA SUPPLEMENT · P230026/S003

Lacrosse NSE ALPHA Coronary Dilatation Catheter

NIPRO VASCULAR CORPORATION (formerly Goodman Co., Ltd.) · Decision date Jul 22, 2026

FDA DECISIONP230026/S003

What did the FDA decide?

FDA records P230026/S003 as a supplement to PMA P230026, with the supplement type “30-Day Notice”. The recorded decision is OK30 (30-day notice), dated Jul 22, 2026.

FDA approval order statement

a cleanroom renovation (new equipment) and the relocation of a dust collector machine
Regulatory pathway
PMA supplement
Supplement type
30-Day Notice
Clinical specialty
Cardiovascular
Decision date
Jul 22, 2026
FDA change category
Process Change - Manufacturer/Sterilizer/Packager/Supplier

FDA source record

Regulatory record facts

Identifier
P230026/S003
Regulatory pathway
PMA supplement
Product code
NWX
Decision code
OK30
Decision date
Jul 22, 2026
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: Catheter, percutaneous transluminal coronary angioplasty (ptca), cutting/scoring.

Product code
NWX
FDA device class
3

Review the original FDA PMA listing for the original approval scope and linked supplements.

FDA decision timeline

  1. P230026/S003 received

    Application receipt date recorded by FDA.

  2. P230026/S004 · Related supplement

    Lacrosse NSE ALPHA Coronary Dilatation Catheter

  3. P230026/S005 · Related supplement

    Lacrosse NSE ALPHA Coronary Dilatation Catheter

  4. P230026/S003 · FDA decision

    30-Day Notice

Timeline entries are records held by MedtechLedger for P230026. View FDA’s full supplement list.

Related devices and submissions

Same PMA: P230026

Explore the linked device profile

Other records with product code NWX

Product / regulatory recordCompanyPathwayDecision dateSource
OrbusNeich Medical (Shenzhen) Co., Ltd.PMA supplementJul 31, 2026FDA
Boston Scientific CorpPMA supplementJan 27, 2026FDA
Boston Scientific CorpPMA supplementDec 1, 2025FDA
OrbusNeich Medical (Shenzhen) Co., Ltd.PMA supplementOct 29, 2025FDA

A shared product code identifies a classification relationship; it does not establish clinical equivalence.

Regulatory context

A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

NIPRO VASCULAR CORPORATION (formerly Goodman Co., Ltd.)

Headquarters
Not reported
Brand website
Not reported
FDA applicant address
5f Kdx Nagoya Sakae Bldg., 4-5-3, Sakae, Naka-Ku, Nagoya

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records